BB Biotech (BION.SW) trades at CHF 46.00 ahead of earnings: what to watch at 17:30 CET

BION.SW stock is trading CHF 46.00 intraday on the SIX in Switzerland ahead of BB Biotech AG’s earnings due later today. The shares are down 0.22% and have traded 67,956 shares so far. Investors should watch portfolio updates, dividend guidance, and any repositioning by Bellevue Asset Management. This earnings report can move the price versus the 50-day average CHF 46.36 and the 200-day average CHF 37.76.

BION.SW stock: earnings timing and what to watch

BB Biotech (BION.SW) reports after Swiss hours on 20 Feb 2026, with the company set to publish results at 17:30 CET. Expect commentary on portfolio valuation and realised gains, which historically drive NAV shocks.

Watch for updates to holdings in core biotech names, changes to net asset value, and any revision to the dividend per share CHF 1.80. Those items will link directly to short-term share moves.

Earnings drivers and portfolio update for BION.SW stock

BB Biotech is an equity fund managed by Bellevue Asset Management. The fund invests globally in biotech equities and benefits when sector catalysts drive re-ratings.

Key earnings drivers include realised gains, changes to fair value of holdings, and realised currency effects. Any increased exposure to high-growth drug developers could shift risk and return profiles.

Valuation and key financials for BION.SW stock

The stock trades at PE 15.23 and shows EPS 3.02 on the exchange quote. Book value per share is CHF 33.64, giving a PB ~1.36 and supporting a value floor.

Market cap is CHF 2,536,865,408.00 and dividend yield sits near 3.93%. These metrics frame both income and NAV-driven investment cases.

Technical and intraday trading snapshot for BION.SW stock

Intraday range is CHF 45.40–46.20 with previous close CHF 46.10. The 50-day average is CHF 46.36 and the 200-day average is CHF 37.76.

Momentum indicators are neutral: RSI 47.85, MACD histogram -0.16, and ATR 1.12 CHF. Average volume is 83,305 vs current 67,956, so intraday liquidity is modest.

Meyka AI grade and analyst consensus on BION.SW stock

Meyka AI rates BION.SW with a score of 69.50 out of 100 (Grade B, HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus.

Third-party screening assigns a firm rating of C on 19 Feb 2026, reflecting mixed DCF and return metrics. Use the Meyka grade as an analytical input, not investment advice.

Price targets and Meyka AI forecast for BION.SW stock

Meyka AI’s forecast model projects a quarterly price of CHF 47.62 and a yearly price of CHF 40.33. The quarterly figure implies an upside of 3.52% versus the current CHF 46.00.

We show a conservative price target CHF 40.00, a base target CHF 48.00, and a bullish target CHF 55.00. Forecasts are model-based projections and not guarantees.

Final Thoughts

BB Biotech AG (BION.SW) enters today’s earnings with the stock at CHF 46.00 and modest intraday weakness. Key numbers to watch are EPS 3.02, PE 15.23, book value CHF 33.64, and the dividend CHF 1.80. Meyka AI’s short-term forecast at CHF 47.62 implies a 3.52% upside, while the yearly model at CHF 40.33 implies a -12.41% downside. NAV commentary and any realised gains will likely determine today’s move on the SIX in Switzerland. Use the Meyka AI grade and technical snapshot to size trades, and remember forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.